Skip to main content
BICYCLE THERAPEUTICS PLC logo

BICYCLE THERAPEUTICS PLC — Investor Relations & Filings

Ticker · BCYC ISIN · US0887861088 LEI · 213800XKUI6R7GKC3E43 US Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2020-03-10 Earnings Release
Country GB United Kingdom
Listing US BCYC

About BICYCLE THERAPEUTICS PLC

https://www.bicycletherapeutics.com/

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines known as Bicycle® molecules. These are fully synthetic bicyclic peptides engineered to combine the targeting specificity and pharmacological properties of large molecule biologics with the rapid and deep tissue penetration of small molecules. The company's proprietary platform creates precision-guided therapeutics to address diseases underserved by existing treatments. The primary focus of its development pipeline is in oncology, with a portfolio of candidates designed to target solid tumors. Beyond oncology, Bicycle Therapeutics leverages its technology through collaborations to explore applications in other therapeutic areas, including anti-infectives, cardiovascular diseases, and central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 10, 2020, reporting the issuance of a press release announcing financial results for the fiscal quarter and year ended December 31, 2019. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The length of the document is 3927 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, this type of document is best classified as an Earnings Release (ER) since it announces quarterly and annual financial results highlights via a press release, but the full details are in the attached exhibit. The document is not the full annual report (10-K) or interim report (IR), nor is it a regulatory filing of a different nature. Therefore, the appropriate classification is ER with high confidence.
2020-03-10 English
FORM 8-K
Legal Proceedings Report Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events that shareholders should know about. The content describes a legal judgment related to ongoing litigation involving the company and its subsidiary, including details about patent license agreements, court rulings, and injunctions. There is no financial data, earnings information, or management discussion of financial results. The primary focus is on legal proceedings and their implications. Therefore, this document fits best under the category of Legal Proceedings Report (LTR). The document length (6694 characters) and detailed narrative support this classification rather than a brief announcement or other report types.
2020-02-28 English
FORM 4 SUBMISSION
Director's Dealing
2020-02-25 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or material definitive agreements by a company. The text describes the entry into a material definitive agreement (a collaboration and license agreement with Genentech) and includes details about the terms of the agreement, payments, milestones, and termination rights. It also references a press release attached as an exhibit. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a proxy, earnings release, or management discussion. It is a regulatory filing announcing a material event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7620 characters) and content confirm it is not a brief announcement but a detailed current report, still fitting the RNS category as per the definitions and rules provided.
2020-02-25 English
SC 13G
Major Shareholding Notification
2020-02-04 English
SC 13G
Major Shareholding Notification
2020-01-30 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.